

Serina Therapeutics Retains Evolution Venture Partners for Follow-on Financing of \$ 30 M

Huntsville, AL, June 27, 2017

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZTM), announced today that Evolution Venture Partners has been retained as the exclusive agent for a follow-on financing in the second half of 2017.

“I am delighted to announce we have retained Evolution Venture Partners as our exclusive investment bank to lead the follow-on financing of \$ 30 M in the second half of 2017,” said Dr. Moreadith. “The executive management team at EVP has an outstanding track record of working with companies like Serina to raise capital and grow the company to the next stage.”

SER-214, a first-in-class drug candidate that delivers rotigotine continuously following a single weekly subcutaneous administration, is Serina’s most advanced clinical program. The Phase Ia program in patients with Parkinson’s disease has completed enrollment, and Serina plans to advance SER-214 into Phase II development in 2017-2018 for both Parkinson’s disease and restless leg syndrome.

Serina plans to advance two of its pipeline programs through IND-enabling studies in 2017 and initiate Phase Ia studies for post-operative pain and refractory epilepsy in 2018. In addition to a growing pipeline of proprietary programs, Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ platform and is actively seeking new partnerships.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that has developed novel polymer therapeutics based on its proprietary polyoxazoline (POZTM) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. POZTM technology provides strong differential characteristics that may demonstrate improved safety, tolerability and clinical benefits versus PEG and other polymer-based technologies.

About Evolution Venture Partners

Evolution Venture Partners is a healthcare investment banking boutique dedicated to evolving, growing and transforming our clients for the benefit of their customers and stakeholders, with a focus on creating value for all participants involved in our transactions or advisory activities.

companies across all areas of healthcare, biotechnology, health and wellness and technology. We work diligently to create successful outcomes in the areas of capital formation, licensing, partnering, M&A and strategic advisory services

We view our clients as our partners and consider ourselves as collaborators in a creative process, taking advantage of a unique network of experts, advisors, investors and corporate executives to design a custom solution for each company.

For more information on Evolution Venture Partners, please visit www.evovp.com.

